Heloisa Helena Milioli

Has grant

University of New South Wales
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Exploiting mechanisms of chemotherapy resistance: new strategies to cure cancer

Open Date: 2024-01-01

Close Date: 2024-12-01

Grant: Open

Targeting cellular plasticity to prevent and treat chemotherapy-resistant disease

Open Date: 2023-01-01

Close Date: 2026-12-01

Grant: Close

Targeting the p53 pathway in the age of CDK4/6 inhibitor resistant ER positive breast cancer

Open Date: 2019-01-01

Close Date: 2021-12-01

Grant: Close

Expanding the repertoire of therapies targeting sex steroid receptors in breast cancer

Open Date: 2018-01-01

Close Date: 2020-12-01

Articles (9)

Year:

2026

Year:

2026

CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease progression remain poorly understood. Here, we performed unbiased genome-wide CRISPR/Cas9 knockout screens using endocrine sensitive ER+ breast cancer cells to identify novel drivers of resistance to combination endocrine therapy (tamoxifen) and CDK4/6 inhibitor (palbociclib) treatment. Our screens identified the inactivation of JNK signalling, including loss of the kinase MAP2K7 , as a key driver of drug insensitivity. We developed multiple CRISPR/Cas9 knockout ER+ breast cancer cell lines (MCF-7 and T-47D) to investigate the effects of MAP2K7 and downstream MAPK8 and MAPK9 loss. MAP2K7 knockout increased metastatic burden in vivo and led to impaired JNK-mediated stress responses, as well as promoting cell survival and reducing senescence entry following endocrine therapy and CDK4/6 inhibitor treatment. Mechanistically, this occurred via loss of the AP-1 transcription factor c-JUN, leading to an attenuated response to combination endocrine therapy plus CDK4/6 inhibition. Furthermore, analysis of clinical datasets found that inactivation of the JNK pathway was associated with increased metastatic burden, and low pJNK T183/Y185 activity correlated with a poorer response to systemic endocrine and CDK4/6 inhibitor therapies in both early-stage and metastatic ER+ breast cancer cohorts. Overall, we demonstrate that suppression of JNK signalling enables persistent growth during combined endocrine therapy and CDK4/6 inhibition. Our data provides the pre-clinical rationale to stratify patients based on JNK pathway activity prior to receiving combination endocrine therapy and CDK4/6 inhibition.

Year:

2025

Three-dimensional (3D) epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to counteract therapy resistance remains largely unaddressed. Here, we show that epigenetic therapy with decitabine (5-Aza-mC) suppresses tumor growth in xenograft models of pre-clinical metastatic estrogen receptor positive (ER+) breast tumor. Decitabine-induced genome-wide DNA hypomethylation results in large-scale 3D epigenome deregulation, including de-compaction of higher-order chromatin structure and loss of boundary insulation of topologically associated domains. Significant DNA hypomethylation associates with ectopic activation of ER-enhancers, gain in ER binding, creation of new 3D enhancer–promoter interactions and concordant up-regulation of ER-mediated transcription pathways. Importantly, long-term withdrawal of epigenetic therapy partially restores methylation at ER-enhancer elements, resulting in a loss of ectopic 3D enhancer–promoter interactions and associated gene repression. Our study illustrates the potential of epigenetic therapy to target ER+ endocrine-resistant breast cancer by DNA methylation-dependent rewiring of 3D chromatin interactions, which are associated with the suppression of tumor growth.

Year:

2024

Resistance to endocrine therapies (ET) is common in estrogen receptor (ER)–positive breast cancer, and most relapsed patients die with ET-resistant disease. Although genetic mutations provide explanations for some relapses, mechanisms of resistance remain undefined in many cases. Drug-induced epigenetic reprogramming has been shown to provide possible routes to resistance. By analyzing histone H3 lysine 27 acetylation profiles and transcriptional reprogramming in models of ET resistance, we discovered that selective ER degraders, such as fulvestrant, promote expression of vestigial-like 1 (VGLL1), a coactivator for TEF-1 and AbaA domain (TEAD) transcription factors. VGLL1, acting via TEADs, promoted the expression of genes that drive the growth of fulvestrant-resistant breast cancer cells. Pharmacological disruption of VGLL1–TEAD4 interaction inhibited VGLL1/TEAD-induced transcriptional programs to prevent the growth of resistant cells. EGFR was among the VGLL1/TEAD-regulated genes, and VGLL1-directed EGFR upregulation sensitized fulvestrant-resistant breast cancer cells to EGFR inhibitors. Taken together, these findings identify VGLL1 as a transcriptional driver in ET resistance and advance therapeutic possibilities for relapsed ER+ breast cancer patients. Significance: Transcriptional reprogramming mediated by the upregulation of the TEAD coactivator VGLL1 confers resistance to estrogen receptor degraders in breast cancer but provides alternative therapeutic options for this clinically important patient group.

Year:

2024

Year:

2024

Resistance to endocrine therapies (ET) is common in estrogen receptor (ER)–positive breast cancer, and most relapsed patients die with ET-resistant disease. Although genetic mutations provide explanations for some relapses, mechanisms of resistance remain undefined in many cases. Drug-induced epigenetic reprogramming has been shown to provide possible routes to resistance. By analyzing histone H3 lysine 27 acetylation profiles and transcriptional reprogramming in models of ET resistance, we discovered that selective ER degraders, such as fulvestrant, promote expression of vestigial-like 1 ( VGLL1 ), a coactivator for TEF-1 and AbaA domain (TEAD) transcription factors. VGLL1, acting via TEADs, promoted the expression of genes that drive the growth of fulvestrant-resistant breast cancer cells. Pharmacological disruption of VGLL1–TEAD4 interaction inhibited VGLL1/TEAD-induced transcriptional programs to prevent the growth of resistant cells. EGFR was among the VGLL1/TEAD-regulated genes, and VGLL1-directed EGFR upregulation sensitized fulvestrant-resistant breast cancer cells to EGFR inhibitors. Taken together, these findings identify VGLL1 as a transcriptional driver in ET resistance and advance therapeutic possibilities for relapsed ER + breast cancer patients. Significance: Transcriptional reprogramming mediated by the upregulation of the TEAD coactivator VGLL1 confers resistance to estrogen receptor degraders in breast cancer but provides alternative therapeutic options for this clinically important patient group.

Year:

2024

Year:

2023

Year:

2023

Collaborators (23)

Liz Caldon

University of New South Wales

AUSTRALIA
View details

Robin Anderson

Head

La Trobe University

AUSTRALIA
View details

Geraldine Laven-Law

Flinders University

AUSTRALIA
View details

Raoul Charles Coombes

Professor of Medical Oncology

Imperial College London

UNITED KINGDOM
View details

Alyssa Nicholls

University of Cambridge

UNITED KINGDOM
View details

Todd Mitchell

Professor

University of Wollongong

AUSTRALIA
View details

Emily Wong

Head of Regulatory Systems

Victor Chang Cardiac Research Institute

AUSTRALIA
View details

Simak Ali

Imperial College London

UNITED KINGDOM
View details

Christine Chaffer

Program Director

Garvan Institute of Medical Research

AUSTRALIA
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Joanna Achinger-Kawecka

Senior Lecturer

University of South Australia

AUSTRALIA
View details

Elgene Lim

Clinical Academic/Professor of Medicine

University of New South Wales

AUSTRALIA
View details

Sally Shirran

University of St. Andrews

UNITED KINGDOM
View details

Theodore Alexandrov

Assistant Professor

University of California, San Diego

UNITED STATES
View details

Zaklina Kovacevic

University of New South Wales Science

AUSTRALIA
View details

Luca Magnani

Docenti

University of Milan

ITALY
View details

Thuy Mai Van Nguyen

Imperial College London

UNITED KINGDOM
View details

Laki Buluwela

Professor of Cancer Medicine

Imperial College London

UNITED KINGDOM
View details

Emad A Rakha

Professor

University of Nottingham

UNITED KINGDOM
View details

Carolina Gemma

Imperial College London

UNITED KINGDOM
View details

Carla Alves

University of Southern Denmark

DENMARK
View details

Emir Bozkurt

Research Scientist

Virginia Tech

UNITED STATES
View details

Dinny Graham

Senior Research Fellow

University of Sydney

AUSTRALIA
View details